Notice of Public Meeting on the NIOSH Document Titled: “Criteria for a Recommended Standard: Occupational Exposure to Diacetyl and 2,3-pentanedione”, 44338-44339 [2011-18755]
Download as PDF
<![CDATA[
44338
Federal Register / Vol. 76, No. 142 / Monday, July 25, 2011 / Notices
sectors to provide an inter-sector
perspective of the structure and progress
of NORA to date. This is also an
opportunity to obtain feedback on how
to ensure that NORA realizes its full
impact potential. We are interested in
your comments on NORA processes;
activities and accomplishments; and
opportunities for adjustments for the
future.
Public Comment Period: Comments
must be received by August 31, 2011.
ADDRESSES: Written comments may be
submitted to the NIOSH Docket Office,
Robert A. Taft Laboratories, 4676
Columbia Parkway, MS–C34,
Cincinnati, Ohio 45226. All material
submitted should reference docket
number NIOSH–244 and must be
submitted by August 31, 2011 to be
considered by the Agency. All
electronic comments should be
formatted in Microsoft Word. In
addition, comments may be sent via email to nioshdocket@cdc.gov or by
facsimile to (513) 533–8285. A complete
electronic docket containing all
comments submitted will be available
on the NIOSH Web page at https://
www.cdc.gov/niosh/docket, and
comments will be available in writing
by request. NIOSH includes all
comments received without change in
the electronic docket, including any
personal information.
FOR FURTHER INFORMATION CONTACT: Chia
Chang, NIOSH, telephone (202) 245–
0625, NORAmiddecade@cdc.gov.
Dated: July 13, 2011.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2011–18753 Filed 7–22–11; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number NIOSH–245]
jlentini on DSK4TPTVN1PROD with NOTICES
Notice of Public Meeting on the NIOSH
Document Titled: ‘‘Criteria for a
Recommended Standard:
Occupational Exposure to Diacetyl and
2,3-pentanedione’’
AGENCY: National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of public meeting.
SUMMARY: The National Institute for
Occupational Safety and Health
VerDate Mar<15>2010
16:15 Jul 22, 2011
Jkt 223001
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) will hold
a public meeting to discuss and obtain
comments on the draft document,
‘‘Criteria for a Recommended Standard:
Occupational Exposure to Diacetyl and
2,3-pentanedione’’. A copy of the draft
document will be posted on the Internet
at https://www.cdc.gov/niosh/docket/
review/docket245/default.html for
Docket number NIOSH–245 on August
12, 2011. This notice serves as advance
notice of the meeting and public
comment period.
Table of Contents
Date and Time
Address
Status
Speaker Registration
Agenda
Supplementary Information
I. Matters to Be Discussed
II. Transcripts
III. Public Comment Period
Contact Person for More Information
August 26, 2011, 8
a.m.–4 p.m., Eastern Time. Please note
that public comments may end before
the time indicated, following the last
call for comments. Members of the
public who wish to provide comments
should plan to attend the meeting at the
start time listed.
ADDRESSES: Omni Shoreham, 2500
Calvert, Street NW. (at Connecticut
Avenue) Washington, DC 20008.
Status: The meeting is open to the
public limited only by the space
available. The meeting room
accommodates 150 people. To preregister for the meeting, interested
parties should contact the NIOSH
Docket Office at nioshdocket@cdc.gov or
by fax at (513) 533–8285. Due to limited
space, notification of intent to attend the
meeting must be made to the NIOSH
Docket Office no later than August 19,
2011. Priority for attendance will be
given to those providing oral comments.
Other requests to attend the meeting
will then be accommodated on a firstcome basis.
Speaker Registration: Persons wanting
to provide oral comments on the draft
document should contact the NIOSH
Docket Office at nioshdocket@cdc.gov or
by fax at (513) 533–8285. Presenters will
be permitted approximately 10 minutes,
and will be informed if additional time
becomes available. All requests to
present should contain the name,
address, telephone number, and
relevant business affiliations of the
presenter, and the topic of the
presentation. Oral comments made at
the public meeting must also be
submitted to the NIOSH Docket Office
DATES AND TIME:
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
in writing in order to be considered by
the Agency.
Agenda: The meeting will begin with
an introduction and presentation by
Federal officials, followed by
presentations from attendees who
register to speak. Each speaker will be
limited to ten minutes. If all preregistered presentations are complete
before the end time, there will be an
open session to receive comments from
anyone who has not signed up on the
speaker registration list who may wish
to speak. Open session comments will
also be limited to 10 minutes per
speaker. After the last speaker or at 4
p.m., whichever occurs first, the
meeting will be adjourned.
SUPPLEMENTARY INFORMATION:
I. Matters To Be Discussed
At the public meeting, special
emphasis will be placed on the
following topics:
1. Hazard identification, risk
estimation, and discussion of health
effects for diacetyl and 2,3pentanedione;
2. Basis of the Recommended
Exposure Limit for diacetyl and 2,3pentanedione;
3. Workplaces and occupations where
exposure to diacetyl and 2,3pentanedione occur;
4. Current exposure measurement
methods;
5. Current strategies for controlling
occupational exposure to diacetyl and
2,3-pentanedione: e.g., engineering
controls, work practices, medical
surveillance, and personal protective
equipment;
6. Oral comments provided to NIOSH
on the draft criteria document.
II. Transcripts
Transcripts will be prepared and
posted to NIOSH Docket number 245
approximately 30 days after the
meeting. If a person making a comment
gives his or her name, no attempt will
be made to redact that name. NIOSH
will take reasonable steps to ensure that
individuals making public comments
are aware of the fact that their
comments (including their name, if
provided) will appear in a transcript of
the meeting posted on a public Web site.
Such reasonable steps include: (a) A
statement read at the start of the meeting
stating that transcripts will be posted
and names of speakers will not be
redacted; and (b) A printed copy of the
statement mentioned in (a) above will
be displayed on the table where
individuals sign up to make public
comments. If individuals in making a
statement reveal personal information
(e.g., medical information) about
E:\FR\FM\25JYN1.SGM
25JYN1
Federal Register / Vol. 76, No. 142 / Monday, July 25, 2011 / Notices
themselves, that information will not
usually be redacted. The CDC Freedom
of Information Act coordinator will,
however, review such revelations in
accordance with the Freedom of
Information Act and if deemed
appropriate, will redact such
information. Disclosures of information
concerning third parties will be
redacted.
III. Public Comment Period
Written comments on the document
will be accepted until October 14, 2011
in accordance with the instructions
below. All material submitted to NIOSH
should reference Docket Number
NIOSH–245. All electronic comments
should be formatted as Microsoft Word
or pdf files and make reference to
docket number NIOSH–245. To submit
comments, please use one of these
options:
• Present oral comments at the public
meeting and provide a written copy of
comments to the NIOSH Docket Office.
• Send NIOSH comments using the
online form at https://www.cdc.gov/
niosh/docket/review/docket245/
comments.html.
• Send comments by e-mail to
nioshdocket@cdc.gov?subject=245.
• Facsimile: (513) 533–8285.
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C34 4676
Columbia Parkway, Cincinnati, Ohio
45226.
All information received in response
to this notice will be available for public
examination and copying at, NIOSH
Docket Office, 4676 Columbia Parkway,
Room 111, Cincinnati, Ohio 45226. A
complete electronic docket containing
all comments submitted will be
available on the NIOSH docket home
page at https://www.cdc.gov/niosh/
docket/, and comments will be available
in writing by request. NIOSH includes
all comments received without change
in the docket, including any personal
information provided.
CONTACT PERSON FOR MORE INFORMATION:
jlentini on DSK4TPTVN1PROD with NOTICES
Lauralynn Taylor McKernan, ScD, CIH,
NIOSH, 4676 Columbia Parkway, MS–
C32, Cincinnati, OH 45226, telephone
(513) 533–8542, fax (513) 533–8230, Email LMcKernan@cdc.gov.
Dated: July 19, 2011.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2011–18755 Filed 7–22–11; 8:45 am]
BILLING CODE 4163–19–P
VerDate Mar<15>2010
16:15 Jul 22, 2011
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of Biotechnology Activities;
Recombinant DNA Research: Action
Under the NIH Guidelines for Research
Involving Recombinant DNA Molecules
(NIH Guidelines)
AGENCY: National Institutes of Health,
PHS, Department of Health and Human
Services.
ACTION: Proposed Minor Action under
the NIH Guidelines.
SUMMARY: The Office of Biotechnology
Activities (OBA) is updating Appendix
B of the NIH Guidelines by specifying
the risk group (RG) classification for
several common attenuated strains of
bacteria and viruses that are frequently
used in recombinant DNA research.
OBA is also adding the risk group for
several viruses not previously listed in
Appendix B. The NIH Guidelines
provide guidance to investigators and
local Institutional Biosafety Committees
(IBCs) for setting containment for
recombinant DNA research. Section II–
A, Risk Assessment, instructs
investigators and IBCs to make an initial
risk assessment based on the RG of the
agent (see Appendix B, Classification of
Human Etiologic Agents on the Basis of
Hazard). The RG of the agent often
establishes the minimum containment
level required for experiments subject to
the NIH Guidelines.
The classification of agents into
various RG categories is based largely on
their ability to cause human disease and
the availability of treatments for that
disease. For the most part, the
organisms listed in Appendix B are
wild-type, non-attenuated strains and a
distinction is not made between the RG
classification for the wild-type organism
and a corresponding attenuated strain.
A few attenuated strains of organisms
are classified in Appendix B at a lower
RG than that of the parental organism.
However, there are a number of
additional, well-established attenuated
strains employed in research subject to
the NIH Guidelines that are not
specifically listed and thus by default
are included in the same RG as the wildtype organism. Therefore, the biosafety
level (BL) specified for research subject
to the NIH Guidelines may be identical
for experimentation with either the
attenuated or the wild-type strain. OBA
has therefore conducted an evaluation
of certain attenuated strains, focusing on
those for which a risk assessment had
been undertaken and containment
recommendations determined in the
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
44339
Centers for Disease Control and
Prevention (CDC)/NIH publication
Biosafety in Microbiological and
Biomedical Laboratories (BMBL) (5th
edition). Specifying the risk groups for
these attenuated strains in Appendix B
of the NIH Guidelines will lead to more
uniform containment recommendations
that are commensurate with the
biosafety risk. In addition, OBA has
identified several RG3 viruses that are
not currently specified in Appendix B
or are currently specified as a member
of a family of viruses otherwise
classified as RG2. Therefore, Appendix
B is being updated to address these
viruses as well.
In addition to considering the risk
assessment articulated in the BMBL,
OBA also consulted with members of
the NIH Recombinant DNA Advisory
Committee (RAC) as well as other
subject matter experts from NIH, CDC,
and academia. Of note, the RAC
discussed the appropriate containment
for two attenuated strains of Yersinia
pestis (lcr(¥) and pgm(¥) mutants) at its
June 16, 2010, meeting when the
committee considered which antibiotic
markers could be used in these strains
without requiring RAC review under
Section III–A–1-a. (A webcast of that
discussion is available at https://
oba.od.nih.gov/rdna_rac/
rac_past_meetings_2010.html.) The
RAC recommendations regarding
containment for work with these
attenuated strains of Yersinia pestis are
being implemented by amending
Appendix B to indicate that these
specific strains are RG2 organisms
rather than RG3 organisms.
This update does not include all
attenuated strains identified in the
BMBL. OBA has tried to select
attenuated strains commonly used in
recombinant DNA research. OBA has
also not modified the RG for viruses for
which the NIH Guidelines already
provides specific containment
recommendations. For example, human
immunodeficiency virus (HIV) is
currently classified as a RG3 virus in
Appendix B of the NIH Guidelines.
However, Section II–A–3 makes specific
recommendations regarding when BL2
is acceptable for research with HIV and
OBA’s guidance titled Biosafety
Considerations for Research with
Lentiviral Vectors (see https://
oba.od.nih.gov/rdna_rac/
rac_guidance_lentivirus.html) provides
additional containment
recommendations for lentiviral vectors
derived from HIV.
Revision of Appendix B is considered
a Minor Action under Section IV–C–3 of
the NIH Guidelines and therefore can be
implemented by OBA after consultation
E:\FR\FM\25JYN1.SGM
25JYN1
]]>Agencies
[Federal Register Volume 76, Number 142 (Monday, July 25, 2011)]
[Notices]
[Pages 44338-44339]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-18755]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number NIOSH-245]
Notice of Public Meeting on the NIOSH Document Titled: ``Criteria
for a Recommended Standard: Occupational Exposure to Diacetyl and 2,3-
pentanedione''
AGENCY: National Institute for Occupational Safety and Health (NIOSH),
Centers for Disease Control and Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC) will
hold a public meeting to discuss and obtain comments on the draft
document, ``Criteria for a Recommended Standard: Occupational Exposure
to Diacetyl and 2,3-pentanedione''. A copy of the draft document will
be posted on the Internet at https://www.cdc.gov/niosh/docket/review/docket245/default.html for Docket number NIOSH-245 on August 12, 2011.
This notice serves as advance notice of the meeting and public comment
period.
Table of Contents
Date and Time
Address
Status
Speaker Registration
Agenda
Supplementary Information
I. Matters to Be Discussed
II. Transcripts
III. Public Comment Period
Contact Person for More Information
DATES and Time: August 26, 2011, 8 a.m.-4 p.m., Eastern Time. Please
note that public comments may end before the time indicated, following
the last call for comments. Members of the public who wish to provide
comments should plan to attend the meeting at the start time listed.
ADDRESSES: Omni Shoreham, 2500 Calvert, Street NW. (at Connecticut
Avenue) Washington, DC 20008.
Status: The meeting is open to the public limited only by the space
available. The meeting room accommodates 150 people. To pre-register
for the meeting, interested parties should contact the NIOSH Docket
Office at nioshdocket@cdc.gov or by fax at (513) 533-8285. Due to
limited space, notification of intent to attend the meeting must be
made to the NIOSH Docket Office no later than August 19, 2011. Priority
for attendance will be given to those providing oral comments. Other
requests to attend the meeting will then be accommodated on a first-
come basis.
Speaker Registration: Persons wanting to provide oral comments on
the draft document should contact the NIOSH Docket Office at
nioshdocket@cdc.gov or by fax at (513) 533-8285. Presenters will be
permitted approximately 10 minutes, and will be informed if additional
time becomes available. All requests to present should contain the
name, address, telephone number, and relevant business affiliations of
the presenter, and the topic of the presentation. Oral comments made at
the public meeting must also be submitted to the NIOSH Docket Office in
writing in order to be considered by the Agency.
Agenda: The meeting will begin with an introduction and
presentation by Federal officials, followed by presentations from
attendees who register to speak. Each speaker will be limited to ten
minutes. If all pre-registered presentations are complete before the
end time, there will be an open session to receive comments from anyone
who has not signed up on the speaker registration list who may wish to
speak. Open session comments will also be limited to 10 minutes per
speaker. After the last speaker or at 4 p.m., whichever occurs first,
the meeting will be adjourned.
SUPPLEMENTARY INFORMATION:
I. Matters To Be Discussed
At the public meeting, special emphasis will be placed on the
following topics:
1. Hazard identification, risk estimation, and discussion of health
effects for diacetyl and 2,3-pentanedione;
2. Basis of the Recommended Exposure Limit for diacetyl and 2,3-
pentanedione;
3. Workplaces and occupations where exposure to diacetyl and 2,3-
pentanedione occur;
4. Current exposure measurement methods;
5. Current strategies for controlling occupational exposure to
diacetyl and 2,3-pentanedione: e.g., engineering controls, work
practices, medical surveillance, and personal protective equipment;
6. Oral comments provided to NIOSH on the draft criteria document.
II. Transcripts
Transcripts will be prepared and posted to NIOSH Docket number 245
approximately 30 days after the meeting. If a person making a comment
gives his or her name, no attempt will be made to redact that name.
NIOSH will take reasonable steps to ensure that individuals making
public comments are aware of the fact that their comments (including
their name, if provided) will appear in a transcript of the meeting
posted on a public Web site. Such reasonable steps include: (a) A
statement read at the start of the meeting stating that transcripts
will be posted and names of speakers will not be redacted; and (b) A
printed copy of the statement mentioned in (a) above will be displayed
on the table where individuals sign up to make public comments. If
individuals in making a statement reveal personal information (e.g.,
medical information) about
[[Page 44339]]
themselves, that information will not usually be redacted. The CDC
Freedom of Information Act coordinator will, however, review such
revelations in accordance with the Freedom of Information Act and if
deemed appropriate, will redact such information. Disclosures of
information concerning third parties will be redacted.
III. Public Comment Period
Written comments on the document will be accepted until October 14,
2011 in accordance with the instructions below. All material submitted
to NIOSH should reference Docket Number NIOSH-245. All electronic
comments should be formatted as Microsoft Word or pdf files and make
reference to docket number NIOSH-245. To submit comments, please use
one of these options:
Present oral comments at the public meeting and provide a
written copy of comments to the NIOSH Docket Office.
Send NIOSH comments using the online form at https://www.cdc.gov/niosh/docket/review/docket245/comments.html.
Send comments by e-mail to
nioshdocket@cdc.gov?subject=245.
Facsimile: (513) 533-8285.
Mail: NIOSH Docket Office, Robert A. Taft Laboratories,
MS-C34 4676 Columbia Parkway, Cincinnati, Ohio 45226.
All information received in response to this notice will be
available for public examination and copying at, NIOSH Docket Office,
4676 Columbia Parkway, Room 111, Cincinnati, Ohio 45226. A complete
electronic docket containing all comments submitted will be available
on the NIOSH docket home page at https://www.cdc.gov/niosh/docket/, and
comments will be available in writing by request. NIOSH includes all
comments received without change in the docket, including any personal
information provided.
CONTACT PERSON FOR MORE INFORMATION: Lauralynn Taylor McKernan, ScD,
CIH, NIOSH, 4676 Columbia Parkway, MS-C32, Cincinnati, OH 45226,
telephone (513) 533-8542, fax (513) 533-8230, E-mail LMcKernan@cdc.gov.
Dated: July 19, 2011.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2011-18755 Filed 7-22-11; 8:45 am]
BILLING CODE 4163-19-P
